UB Paderborn / Katalog / Suche / in CDI

Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis

Nature medicine, 2018-12, Vol.24 (12), p.1804-1808

2018

Link zum Volltext

Verfügbarkeit prüfen

Interdependent IL-7 and IFN-γ signalling in T-cell controls tumour eradication by combined α-CTLA-4+α-PD-1 therapy

Nature communications, 2016-08, Vol.7 (1), p.12335-12335, Article 12335

2016

Link zum Volltext

Verfügbarkeit prüfen

Protein Kinase C Epsilon Cooperates with PTEN Loss for Prostate Tumorigenesis through the CXCL13-CXCR5 Pathway

Cell reports (Cambridge), 2017-04, Vol.19 (2), p.375-388

2017

Link zum Volltext

Verfügbarkeit prüfen

Phase 1b study of pegylated arginine deiminase (ADI-PEG 20) plus Pembrolizumab in advanced solid cancers

Oncoimmunology, 2021-01, Vol.10 (1), p.1943253

2021

Link zum Volltext

Verfügbarkeit prüfen

Cooperation between Stat3 and Akt Signaling Leads to Prostate Tumor Development in Transgenic Mice

Neoplasia (New York, N.Y.), 2011-03, Vol.13 (3), p.254-IN12

2011

Link zum Volltext

Verfügbarkeit prüfen

ARID1A mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC

Science translational medicine, 2020-06, Vol.12 (548)

2020

Link zum Volltext

Verfügbarkeit prüfen

COX-2 mediates pro-tumorigenic effects of PKCε in prostate cancer

Oncogene, 2018-08, Vol.37 (34), p.4735-4749

2018

Link zum Volltext

Verfügbarkeit prüfen

Stearoyl gemcitabine nanoparticles overcome obesity-induced cancer cell resistance to gemcitabine in a mouse postmenopausal breast cancer model

Cancer biology & therapy, 2013-04, Vol.14 (4), p.357-364

2013

Link zum Volltext

Verfügbarkeit prüfen

Antitumor Activity of Tumor-Targeted RNA Replicase-Based Plasmid That Expresses Interleukin‑2 in a Murine Melanoma Model

Molecular pharmaceutics, 2013-06, Vol.10 (6), p.2404-2415

2013

Link zum Volltext

Verfügbarkeit prüfen

Characterization and Comparison of GITR Expression in Solid Tumors

Clinical cancer research, 2019-11, Vol.25 (21), p.6501-6510

2019

Link zum Volltext

Verfügbarkeit prüfen

COX-2 mediates pro-tumorigenic effects of PKC[epsilon] in prostate cancer

Oncogene, 2018-08, Vol.37 (34), p.4735

2018

Link zum Volltext

Verfügbarkeit prüfen

Combinatorial biomarkers to predict responses to immune checkpoint therapy in metastatic urothelial cancer

Journal of clinical oncology, 2021-02, Vol.39 (6_suppl), p.488-488

2021

Link zum Volltext

Verfügbarkeit prüfen

Immune analysis of fibrolamellar hepatocellular carcinoma

Journal of clinical oncology, 2017-02, Vol.35 (4_suppl), p.324-324

2017

Link zum Volltext

Verfügbarkeit prüfen

Randomized, open-label, perioperative phase II study evaluating nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC

Journal of clinical oncology, 2019-03, Vol.37 (8_suppl), p.52-52

2019

Link zum Volltext

Verfügbarkeit prüfen

Randomized, open-label, perioperative phase II study evaluating nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC

Journal of clinical oncology, 2019-02, Vol.37 (4_suppl), p.185-185

2019

Link zum Volltext

Verfügbarkeit prüfen

Abstract 5423: Diet induced obesity, inflammation and prostate cancer progression in Hi-Myc mice

Cancer research (Chicago, Ill.), 2012-04, Vol.72 (8_Supplement), p.5423-5423

2012

Link zum Volltext

Verfügbarkeit prüfen

Association of PIK3CA mutations (mut) with immune engagement and clinical benefit from immunotherapy in microsatellite stable (MSS) colorectal cancer (CRC) patients (pts)

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.3604-3604

2019

Link zum Volltext

Verfügbarkeit prüfen

Final results of a randomized, open label, perioperative phase II study evaluating nivolumab alone or nivolumab plus ipilimumab in patients with resectable HCC

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.4599-4599

2020

Link zum Volltext

Verfügbarkeit prüfen

Randomized, open-label, perioperative phase II study evaluating nivolumab alone or nivolumab plus ipilimumab in patients with resectable HCC

Journal of clinical oncology, 2020-02, Vol.38 (4_suppl), p.486-486

2020

Link zum Volltext

Verfügbarkeit prüfen

Prognostic implications of TAMs in colorectal cancer hepatic metastases

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.3574-3574

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract 179: Impact of diet-induced obesity on inflamatory pathways during prostate cancer progression in Hi-Myc mice

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.179-179

2013

Link zum Volltext

Verfügbarkeit prüfen

Ablative therapy to induce local and systemic immune changes in patients with metastatic renal cell carcinoma

Journal of clinical oncology, 2017-02, Vol.35 (6_suppl), p.505-505

2017

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis

Interdependent IL-7 and IFN-γ signalling in T-cell controls tumour eradication by combined α-CTLA-4+α-PD-1 therapy

Protein Kinase C Epsilon Cooperates with PTEN Loss for Prostate Tumorigenesis through the CXCL13-CXCR5 Pathway

Phase 1b study of pegylated arginine deiminase (ADI-PEG 20) plus Pembrolizumab in advanced solid cancers

Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma

Cooperation between Stat3 and Akt Signaling Leads to Prostate Tumor Development in Transgenic Mice

ARID1A mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC

COX-2 mediates pro-tumorigenic effects of PKCε in prostate cancer

Author Correction: Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis

Stearoyl gemcitabine nanoparticles overcome obesity-induced cancer cell resistance to gemcitabine in a mouse postmenopausal breast cancer model

Antitumor Activity of Tumor-Targeted RNA Replicase-Based Plasmid That Expresses Interleukin‑2 in a Murine Melanoma Model

Characterization and Comparison of GITR Expression in Solid Tumors

COX-2 mediates pro-tumorigenic effects of PKC[epsilon] in prostate cancer

Combinatorial biomarkers to predict responses to immune checkpoint therapy in metastatic urothelial cancer

Immune analysis of fibrolamellar hepatocellular carcinoma

Randomized, open-label, perioperative phase II study evaluating nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC

Randomized, open-label, perioperative phase II study evaluating nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC

Abstract 5423: Diet induced obesity, inflammation and prostate cancer progression in Hi-Myc mice

Association of PIK3CA mutations (mut) with immune engagement and clinical benefit from immunotherapy in microsatellite stable (MSS) colorectal cancer (CRC) patients (pts)

Final results of a randomized, open label, perioperative phase II study evaluating nivolumab alone or nivolumab plus ipilimumab in patients with resectable HCC

Randomized, open-label, perioperative phase II study evaluating nivolumab alone or nivolumab plus ipilimumab in patients with resectable HCC

Prognostic implications of TAMs in colorectal cancer hepatic metastases

Abstract 179: Impact of diet-induced obesity on inflamatory pathways during prostate cancer progression in Hi-Myc mice

Ablative therapy to induce local and systemic immune changes in patients with metastatic renal cell carcinoma

A pilot presurgical study evaluating anti-PD-L1 durvalumab (durva) plus anti-CTLA-4 tremelimumab (treme) in patients (pts) with high-risk muscle-invasive bladder carcinoma (MIBC) who are ineligible for cisplatin-based neoadjuvant chemotherapy (NAC)

Suchergebnisse filtern